History Introducing NEXEL’s History

2020’s

  • May
    MoU signed with Chonnam National University Hospital
    Apr
    Strategic partnership with Nanion Technologies to open reference lab in Korea for CardioExcyte96 FLEXcyte96

2019’s

  • Aug
    Completed Series B funding
    May
    Novartis drug development team(VP level) visits NEXEL HQ
    Mar
    Distribution agreement signed with Cambridge Bioscience in the U.K. and Ireland for hiPSC-derived cell products

2018’s

  • Jun
    Innobiz Certification
    May
    Commercial license (non-exclusive) for hiPSC-derived cell products obtained from iPS Academia Japan
    Mar
    ISO9001 certification

2017’s

  • Dec
    Completed Series A funding
    Sep
    Invited to Novo Nordisk global collaboration business (with KOTRA)
    Aug
    MoU signed with T&R Biofab for the development of bioprinting technology using stem-cell derived cells
    May
    Distribution agreement with BOYA Medical for the distribution of iPSC-derived cell products
    Jan
    Domestic launch of cell products

2016’s

  • Dec
    Tech. transfer of 6 patents from Korea University Industry-Academic Cooperation Foundation
    Nov
    License-in of cardiomyocyte differentiation technology from KIT
    Sep
    MoU signed for the development of toxicology platfoms using stem-cell derived cells with Korea Institute of Toxicology (KIT)
    Mar
    Corporate affiliated research institute certified
    Feb
    Venture company certified

2015’s

  • May
    Name changed to NEXEL Co., Ltd.

2014’s

  • Nov
    Picked as family company to Korea University Life Sciences College
    Sep
    MoU signed with IMPLAD China

2013’s

  • Mar
    MoU signed with Korea University

2012’s

  • Sep
    Founding of NEXCELL Bio
  • logoCONTACT

    Contact Information

    • Address: 8F, 55 Magokdong-ro, Gangseo-gu, Seoul, Republic of Korea(07802)

    • Business Registration No.: 109-86-37282
    • CEO: Choongseong Han

    • Tel: +82-2-2088-8886
    • Fax: +82-2-2088-8884
    • E-mail: support@nexel.co.kr